BFLY — Butterfly Network, Inc. Company Overview

Executive Summary

Butterfly Network, Inc. (NYSE: BFLY) is the pioneer of "Ultrasound-on-Chip" semiconductor-based handheld ultrasound imaging, positioning itself against a legacy industry built on cart-based systems and piezoelectric-crystal handheld probes. For fiscal 2025, Butterfly generated $97.6 million in revenue, up from $82.1 million in 2024, while still posting a net loss of $77.1 million against an accumulated deficit of $879.2 million — underscoring a company that has achieved real commercial traction but has not yet reached profitability. The company's single-probe, whole-body-imaging devices (iQ+, iQ3), enterprise software (Compass AI), and expansion into home care and veterinary markets represent an attempt to convert its core chip IP into a multi-vector growth story beyond traditional point-of-care ultrasound.

Core Business Model

Butterfly's business model combines hardware sales with recurring software subscriptions, structurally resembling a "razor-and-blade" model layered onto medical-device distribution. Devices are sold directly through a targeted regional sales force to hospital systems and academic institutions, through eCommerce for individual practitioners and veterinarians, and through international distributor partnerships covering roughly 70 countries. Software is monetized separately: Core Technology subscriptions run approximately $300/year and Advanced Technology subscriptions approximately $420/year, layering recurring revenue on top of one-time hardware sales. The semiconductor-based design is the structural differentiator — housing thousands of micro-machined ultrasonic transducers directly on a chip (rather than piezoelectric crystals) allows a single probe to image the whole body, in principle reducing both manufacturing complexity and the multi-probe cost burden that afflicts traditional handheld competitors.

Business Segments

Butterfly does not report discrete financial segments but organizes its go-to-market around distinct customer verticals: hospital/health-system enterprise accounts (its largest and most strategically prioritized channel, deepened through the Compass AI enterprise platform), individual practitioner/clinician sales via eCommerce, an international distributor channel, a newer veterinary line (iQ3 Vet, launched October 2025), and a HomeCare Services business (launched March 2024) targeting chronic disease management outside traditional clinical settings. Approximately 11% of 2025 revenue came from a single customer, and the majority of revenue remains U.S.-sourced even as the company markets in over 100 countries.

Product Portfolio

The current hardware lineup includes the Butterfly iQ+ (~$2,700, second-generation, whole-body single-probe imaging), the Butterfly iQ3 (~$3,900, launched February 2024 with the more powerful P4.3 chip and "best-in-class image quality" per company claims), the Butterfly Move cart system (introduced November 2025, letting clinicians dock/undock the iQ3 probe to bridge point-of-care and traditional cart workflows), the iQ+ Bladder specialty scanner, and iQ3 Vet for companion-animal and equine veterinary use. On the software side, Compass AI serves as the enterprise management layer for health systems scaling ultrasound across departments; ScanLab provides AI-powered image-quality feedback for training; and Butterfly Academy/Butterfly Certified deliver structured education and credentialing. The company has also begun licensing its core chip technology through the Butterfly Embedded program into non-competitive adjacent markets such as brain-computer interfaces and surgical robotics — an early-stage optionality play on the underlying IP.

Competitive Landscape

Butterfly competes against two distinct groups. The first is the entrenched cart-based ultrasound incumbents — GE Healthcare, Philips, Siemens Healthineers, and Canon/Fujifilm — whose top-five manufacturers still dominate the traditional, higher-resolution ultrasound market and who have increasingly launched their own handheld products (GE's Vscan Air) to defend share. The second is the direct handheld point-of-care segment, including Philips Lumify, Fujifilm SonoSite iViz, and Clarius, most of which still rely on traditional piezoelectric-crystal probe technology and typically require multiple probes for different body regions. Butterfly's competitive claim rests on single-probe whole-body imaging and a semiconductor manufacturing path that could benefit from Moore's Law-style cost declines, but it remains a subscale challenger relative to GE and Philips in overall ultrasound revenue, and rival handheld products from Clarius and GE have closed image-quality gaps in recent device generations.

Strategic Strengths & Risks

Strengths include genuinely differentiated, patented chip-on-probe technology; a growing enterprise software attach rate (Compass AI) that increases switching costs once a hospital system standardizes workflows on the platform; expansion into adjacent, less-penetrated verticals (veterinary, home care) that diversify the total addressable market beyond acute-care point-of-care ultrasound; and philanthropic/global-health deployments (including a Gates Foundation-funded rollout of 1,000 devices to sub-Saharan Africa) that build brand and long-term market access in underserved regions. Risks are substantial: the company remains unprofitable with a $879.2 million accumulated deficit and continues to burn cash; incumbents with vastly greater R&D and distribution resources are closing the handheld image-quality gap; reimbursement and clinical-workflow adoption for point-of-care ultrasound remains uneven across health systems; and roughly 220 employees (as of January 2026) represents a lean base relative to the ambition of competing across hospital, veterinary, and home-care verticals simultaneously.

Financial Overview

Revenue grew 19% year over year to $97.6 million in fiscal 2025 from $82.1 million in 2024. Net loss widened modestly to $77.1 million from $72.5 million, and the accumulated deficit reached $879.2 million as of December 31, 2025 — a legacy of the company's SPAC-era cash burn and continued R&D/commercial investment. The company has surpassed 145,000 unique Butterfly device users cumulatively and maintains commercial distribution in roughly 70 countries. Customer concentration is modest (approximately 11% of revenue from the largest customer), and the balance of revenue mix continues shifting toward enterprise hospital accounts and recurring software subscriptions, which should support gross margin over time even as the company has not yet demonstrated a clear path to GAAP profitability.

Summary Conclusion

Butterfly Network holds a genuinely differentiated technology position in handheld ultrasound, anchored by patented semiconductor chip-on-probe IP and an expanding software/subscription layer that increases switching costs for enterprise health-system customers. However, the moat remains partial and unproven at scale: incumbents with far greater resources are narrowing the technology gap, the company is still deeply unprofitable, and commercial execution across hospital, veterinary, and home-care channels simultaneously creates real operational risk. Butterfly is best characterized as an emerging-technology challenger with real IP-based differentiation rather than an established moat.